KARE Biosciences

Executive Summary

KARE Biosciences is a private biotechnology company based in San Diego, focused on repurposing approved drugs and developing nutritional supplements for metabolic and cardiovascular diseases. Founded in 2018, the company's lead program involves ramatroban, a thromboxane receptor antagonist originally approved for allergic rhinitis, which is being repurposed for multiple indications including metabolic disease. KARE is also developing a specialized multivitamin formulation for kidney patients. The company has advanced its lead candidate to Phase 3 clinical trials, indicating significant progress and a potential near-term catalyst. With a focus on de-risked repurposing and a growing pipeline, KARE Biosciences aims to address high unmet medical needs in chronic disease areas. KARE's strategy leverages existing safety data to accelerate development timelines and reduce costs. The Phase 3 trial for ramatroban targets a metabolic indication, and positive results could establish a new therapeutic option and drive valuation. The multivitamin for kidney patients, while lower risk, addresses a specific nutritional gap in a large patient population. As a private company, KARE's success hinges on clinical outcomes and potential partnerships. The near-term focus on data readouts and regulatory milestones positions the company for potential value inflection, though execution risk remains given the competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 data readout for ramatroban in metabolic indication60% success
• Q4 2026Regulatory submission for kidney patient multivitamin70% success